nodes	percent_of_prediction	percent_of_DWPC	metapath
Diclofenac—UGT2B7—urinary bladder cancer	0.252	0.578	CbGaD
Diclofenac—CXCL8—urinary bladder cancer	0.142	0.327	CbGaD
Diclofenac—PTGS2—urinary bladder cancer	0.0415	0.0953	CbGaD
Diclofenac—UGT2B7—Epirubicin—urinary bladder cancer	0.0253	0.0771	CbGbCtD
Diclofenac—CYP2B6—Thiotepa—urinary bladder cancer	0.0243	0.0741	CbGbCtD
Diclofenac—SLCO1C1—Methotrexate—urinary bladder cancer	0.024	0.073	CbGbCtD
Diclofenac—ABCC4—Fluorouracil—urinary bladder cancer	0.0209	0.0636	CbGbCtD
Diclofenac—ABCC1—Epirubicin—urinary bladder cancer	0.018	0.0548	CbGbCtD
Diclofenac—UGT1A1—Etoposide—urinary bladder cancer	0.0171	0.0519	CbGbCtD
Diclofenac—ABCB1—Mitomycin—urinary bladder cancer	0.0165	0.0501	CbGbCtD
Diclofenac—ABCC1—Etoposide—urinary bladder cancer	0.014	0.0427	CbGbCtD
Diclofenac—SLC22A11—Methotrexate—urinary bladder cancer	0.0124	0.0377	CbGbCtD
Diclofenac—ABCC4—Methotrexate—urinary bladder cancer	0.0115	0.0351	CbGbCtD
Diclofenac—PTGS2—Cisplatin—urinary bladder cancer	0.0104	0.0318	CbGbCtD
Diclofenac—PTGS2—Etoposide—urinary bladder cancer	0.0103	0.0312	CbGbCtD
Diclofenac—ABCC1—Doxorubicin—urinary bladder cancer	0.00956	0.0291	CbGbCtD
Diclofenac—ABCC1—Methotrexate—urinary bladder cancer	0.00926	0.0282	CbGbCtD
Diclofenac—PTGS1—Etoposide—urinary bladder cancer	0.00866	0.0264	CbGbCtD
Diclofenac—ALB—Fluorouracil—urinary bladder cancer	0.00775	0.0236	CbGbCtD
Diclofenac—CYP3A4—Thiotepa—urinary bladder cancer	0.00748	0.0228	CbGbCtD
Diclofenac—SLC22A8—Methotrexate—urinary bladder cancer	0.0072	0.0219	CbGbCtD
Diclofenac—CYP2B6—Cisplatin—urinary bladder cancer	0.00672	0.0204	CbGbCtD
Diclofenac—CYP2E1—Etoposide—urinary bladder cancer	0.00669	0.0204	CbGbCtD
Diclofenac—CYP2C8—Fluorouracil—urinary bladder cancer	0.00599	0.0182	CbGbCtD
Diclofenac—SLC22A6—Methotrexate—urinary bladder cancer	0.00502	0.0153	CbGbCtD
Diclofenac—CYP2C8—Etoposide—urinary bladder cancer	0.005	0.0152	CbGbCtD
Diclofenac—ABCB1—Gemcitabine—urinary bladder cancer	0.00474	0.0144	CbGbCtD
Diclofenac—CYP1A2—Fluorouracil—urinary bladder cancer	0.00464	0.0141	CbGbCtD
Diclofenac—CYP2B6—Doxorubicin—urinary bladder cancer	0.0045	0.0137	CbGbCtD
Diclofenac—ALB—Methotrexate—urinary bladder cancer	0.00427	0.013	CbGbCtD
Diclofenac—CYP2C9—Fluorouracil—urinary bladder cancer	0.00418	0.0127	CbGbCtD
Diclofenac—CYP1A2—Etoposide—urinary bladder cancer	0.00387	0.0118	CbGbCtD
Diclofenac—CYP2C9—Cisplatin—urinary bladder cancer	0.00355	0.0108	CbGbCtD
Diclofenac—ABCB1—Cisplatin—urinary bladder cancer	0.00344	0.0105	CbGbCtD
Diclofenac—ABCB1—Etoposide—urinary bladder cancer	0.00338	0.0103	CbGbCtD
Diclofenac—TTR—urine—urinary bladder cancer	0.00231	0.0468	CbGeAlD
Diclofenac—ABCB1—Doxorubicin—urinary bladder cancer	0.00231	0.00702	CbGbCtD
Diclofenac—ABCB1—Methotrexate—urinary bladder cancer	0.00224	0.0068	CbGbCtD
Diclofenac—UGT1A1—urine—urinary bladder cancer	0.00219	0.0444	CbGeAlD
Diclofenac—CYP3A4—Etoposide—urinary bladder cancer	0.00203	0.00617	CbGbCtD
Diclofenac—ASIC1—prostate gland—urinary bladder cancer	0.00182	0.0369	CbGeAlD
Diclofenac—SLC22A8—urine—urinary bladder cancer	0.00142	0.0287	CbGeAlD
Diclofenac—CYP3A4—Doxorubicin—urinary bladder cancer	0.00138	0.00421	CbGbCtD
Diclofenac—CYP2C19—urine—urinary bladder cancer	0.00119	0.0241	CbGeAlD
Diclofenac—PLA2G2A—prostate gland—urinary bladder cancer	0.0011	0.0223	CbGeAlD
Diclofenac—CXCL8—prostate gland—urinary bladder cancer	0.00109	0.022	CbGeAlD
Diclofenac—ASIC1—female reproductive system—urinary bladder cancer	0.000995	0.0202	CbGeAlD
Diclofenac—CXCR1—lymph node—urinary bladder cancer	0.000979	0.0198	CbGeAlD
Diclofenac—CYP1A2—urine—urinary bladder cancer	0.00097	0.0196	CbGeAlD
Diclofenac—PLA2G2A—seminal vesicle—urinary bladder cancer	0.00093	0.0188	CbGeAlD
Diclofenac—UGT2B7—prostate gland—urinary bladder cancer	0.000925	0.0187	CbGeAlD
Diclofenac—CYP2C9—urine—urinary bladder cancer	0.000921	0.0187	CbGeAlD
Diclofenac—CYP2E1—urine—urinary bladder cancer	0.000873	0.0177	CbGeAlD
Diclofenac—SCN4A—prostate gland—urinary bladder cancer	0.000853	0.0173	CbGeAlD
Diclofenac—PLA2G2A—epithelium—urinary bladder cancer	0.000808	0.0164	CbGeAlD
Diclofenac—KCNQ3—female reproductive system—urinary bladder cancer	0.000792	0.016	CbGeAlD
Diclofenac—UGT1A1—prostate gland—urinary bladder cancer	0.000787	0.0159	CbGeAlD
Diclofenac—PLA2G2A—smooth muscle tissue—urinary bladder cancer	0.000778	0.0158	CbGeAlD
Diclofenac—CXCL8—smooth muscle tissue—urinary bladder cancer	0.00077	0.0156	CbGeAlD
Diclofenac—ALOX5—prostate gland—urinary bladder cancer	0.000752	0.0152	CbGeAlD
Diclofenac—PLA2G2A—renal system—urinary bladder cancer	0.000749	0.0152	CbGeAlD
Diclofenac—PLA2G2A—urethra—urinary bladder cancer	0.000736	0.0149	CbGeAlD
Diclofenac—KCNQ2—female reproductive system—urinary bladder cancer	0.000729	0.0148	CbGeAlD
Diclofenac—CXCL8—urethra—urinary bladder cancer	0.000729	0.0148	CbGeAlD
Diclofenac—CYP3A4—urine—urinary bladder cancer	0.000702	0.0142	CbGeAlD
Diclofenac—SLCO1C1—renal system—urinary bladder cancer	0.000633	0.0128	CbGeAlD
Diclofenac—UGT2B7—renal system—urinary bladder cancer	0.000631	0.0128	CbGeAlD
Diclofenac—SLC22A11—renal system—urinary bladder cancer	0.000615	0.0124	CbGeAlD
Diclofenac—PLA2G2A—female reproductive system—urinary bladder cancer	0.0006	0.0122	CbGeAlD
Diclofenac—ASIC1—lymph node—urinary bladder cancer	0.000582	0.0118	CbGeAlD
Diclofenac—SCN4A—renal system—urinary bladder cancer	0.000581	0.0118	CbGeAlD
Diclofenac—TTR—renal system—urinary bladder cancer	0.000566	0.0115	CbGeAlD
Diclofenac—CXCL8—vagina—urinary bladder cancer	0.000537	0.0109	CbGeAlD
Diclofenac—UGT1A1—renal system—urinary bladder cancer	0.000536	0.0109	CbGeAlD
Diclofenac—ALOX5—smooth muscle tissue—urinary bladder cancer	0.000532	0.0108	CbGeAlD
Diclofenac—ABCC4—prostate gland—urinary bladder cancer	0.000513	0.0104	CbGeAlD
Diclofenac—SLC22A8—prostate gland—urinary bladder cancer	0.000509	0.0103	CbGeAlD
Diclofenac—UGT2B7—female reproductive system—urinary bladder cancer	0.000505	0.0102	CbGeAlD
Diclofenac—ALOX5—urethra—urinary bladder cancer	0.000503	0.0102	CbGeAlD
Diclofenac—CYP2C18—vagina—urinary bladder cancer	0.000495	0.01	CbGeAlD
Diclofenac—SLC22A11—female reproductive system—urinary bladder cancer	0.000492	0.00997	CbGeAlD
Diclofenac—TTR—female reproductive system—urinary bladder cancer	0.000453	0.00917	CbGeAlD
Diclofenac—ABCC1—prostate gland—urinary bladder cancer	0.000437	0.00885	CbGeAlD
Diclofenac—ALOX5—female reproductive system—urinary bladder cancer	0.00041	0.00831	CbGeAlD
Diclofenac—Bromfenac—PTGS2—urinary bladder cancer	0.000375	0.261	CrCbGaD
Diclofenac—ABCC1—seminal vesicle—urinary bladder cancer	0.00037	0.00749	CbGeAlD
Diclofenac—PLA2G2A—lymph node—urinary bladder cancer	0.000351	0.00711	CbGeAlD
Diclofenac—ABCC4—renal system—urinary bladder cancer	0.000349	0.00708	CbGeAlD
Diclofenac—CXCL8—lymph node—urinary bladder cancer	0.000347	0.00704	CbGeAlD
Diclofenac—SLC22A8—renal system—urinary bladder cancer	0.000347	0.00702	CbGeAlD
Diclofenac—Lumiracoxib—PTGS2—urinary bladder cancer	0.000318	0.222	CrCbGaD
Diclofenac—CYP2E1—prostate gland—urinary bladder cancer	0.000313	0.00635	CbGeAlD
Diclofenac—Nepafenac—PTGS2—urinary bladder cancer	0.000303	0.211	CrCbGaD
Diclofenac—PTGS1—prostate gland—urinary bladder cancer	0.000302	0.00611	CbGeAlD
Diclofenac—SLCO1C1—lymph node—urinary bladder cancer	0.000296	0.006	CbGeAlD
Diclofenac—ABCC1—urethra—urinary bladder cancer	0.000293	0.00593	CbGeAlD
Diclofenac—PTGS2—prostate gland—urinary bladder cancer	0.000289	0.00584	CbGeAlD
Diclofenac—ABCC4—female reproductive system—urinary bladder cancer	0.00028	0.00567	CbGeAlD
Diclofenac—CYP2E1—seminal vesicle—urinary bladder cancer	0.000265	0.00537	CbGeAlD
Diclofenac—PTGS1—seminal vesicle—urinary bladder cancer	0.000255	0.00517	CbGeAlD
Diclofenac—CYP2C8—renal system—urinary bladder cancer	0.000254	0.00514	CbGeAlD
Diclofenac—CYP1A1—epithelium—urinary bladder cancer	0.000252	0.00511	CbGeAlD
Diclofenac—Meclofenamic acid—PTGS2—urinary bladder cancer	0.000248	0.173	CrCbGaD
Diclofenac—PTGS2—seminal vesicle—urinary bladder cancer	0.000244	0.00494	CbGeAlD
Diclofenac—ALOX5—lymph node—urinary bladder cancer	0.00024	0.00486	CbGeAlD
Diclofenac—CYP1A2—renal system—urinary bladder cancer	0.000237	0.00481	CbGeAlD
Diclofenac—CYP1A1—renal system—urinary bladder cancer	0.000234	0.00474	CbGeAlD
Diclofenac—CYP1A1—urethra—urinary bladder cancer	0.00023	0.00466	CbGeAlD
Diclofenac—CYP2B6—renal system—urinary bladder cancer	0.000228	0.00461	CbGeAlD
Diclofenac—PTGS1—epithelium—urinary bladder cancer	0.000222	0.00449	CbGeAlD
Diclofenac—ABCC1—vagina—urinary bladder cancer	0.000216	0.00437	CbGeAlD
Diclofenac—PTGS1—smooth muscle tissue—urinary bladder cancer	0.000214	0.00433	CbGeAlD
Diclofenac—CYP2E1—renal system—urinary bladder cancer	0.000214	0.00432	CbGeAlD
Diclofenac—PTGS2—epithelium—urinary bladder cancer	0.000212	0.00429	CbGeAlD
Diclofenac—CYP2C19—vagina—urinary bladder cancer	0.000211	0.00426	CbGeAlD
Diclofenac—CYP2E1—urethra—urinary bladder cancer	0.00021	0.00425	CbGeAlD
Diclofenac—PTGS1—renal system—urinary bladder cancer	0.000206	0.00417	CbGeAlD
Diclofenac—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000204	0.00414	CbGeAlD
Diclofenac—CYP2C8—female reproductive system—urinary bladder cancer	0.000203	0.00411	CbGeAlD
Diclofenac—PTGS2—renal system—urinary bladder cancer	0.000197	0.00398	CbGeAlD
Diclofenac—PTGS2—urethra—urinary bladder cancer	0.000193	0.00391	CbGeAlD
Diclofenac—Mefenamic acid—PTGS2—urinary bladder cancer	0.000193	0.134	CrCbGaD
Diclofenac—CYP1A1—female reproductive system—urinary bladder cancer	0.000188	0.0038	CbGeAlD
Diclofenac—CYP2C8—vagina—urinary bladder cancer	0.000184	0.00372	CbGeAlD
Diclofenac—CYP2B6—female reproductive system—urinary bladder cancer	0.000182	0.00369	CbGeAlD
Diclofenac—CYP2C9—female reproductive system—urinary bladder cancer	0.00018	0.00365	CbGeAlD
Diclofenac—ABCB1—prostate gland—urinary bladder cancer	0.000178	0.00361	CbGeAlD
Diclofenac—CYP3A4—renal system—urinary bladder cancer	0.000172	0.00348	CbGeAlD
Diclofenac—CYP2E1—female reproductive system—urinary bladder cancer	0.000171	0.00346	CbGeAlD
Diclofenac—CYP1A1—vagina—urinary bladder cancer	0.00017	0.00343	CbGeAlD
Diclofenac—ALB—lymph node—urinary bladder cancer	0.000169	0.00342	CbGeAlD
Diclofenac—CYP2B6—vagina—urinary bladder cancer	0.000165	0.00334	CbGeAlD
Diclofenac—PTGS1—female reproductive system—urinary bladder cancer	0.000165	0.00334	CbGeAlD
Diclofenac—ABCC4—lymph node—urinary bladder cancer	0.000164	0.00332	CbGeAlD
Diclofenac—PTGS2—female reproductive system—urinary bladder cancer	0.000157	0.00319	CbGeAlD
Diclofenac—ABCB1—seminal vesicle—urinary bladder cancer	0.000151	0.00306	CbGeAlD
Diclofenac—PTGS1—vagina—urinary bladder cancer	0.000149	0.00302	CbGeAlD
Diclofenac—PTGS2—vagina—urinary bladder cancer	0.000142	0.00288	CbGeAlD
Diclofenac—ABCC1—lymph node—urinary bladder cancer	0.00014	0.00283	CbGeAlD
Diclofenac—CYP3A4—female reproductive system—urinary bladder cancer	0.000138	0.00279	CbGeAlD
Diclofenac—ABCB1—epithelium—urinary bladder cancer	0.000131	0.00266	CbGeAlD
Diclofenac—ABCB1—renal system—urinary bladder cancer	0.000122	0.00246	CbGeAlD
Diclofenac—ABCB1—urethra—urinary bladder cancer	0.000119	0.00242	CbGeAlD
Diclofenac—CYP1A1—lymph node—urinary bladder cancer	0.00011	0.00222	CbGeAlD
Diclofenac—ABCB1—female reproductive system—urinary bladder cancer	9.74e-05	0.00197	CbGeAlD
Diclofenac—PTGS1—lymph node—urinary bladder cancer	9.64e-05	0.00195	CbGeAlD
Diclofenac—PTGS2—lymph node—urinary bladder cancer	9.21e-05	0.00187	CbGeAlD
Diclofenac—ABCB1—vagina—urinary bladder cancer	8.81e-05	0.00178	CbGeAlD
Diclofenac—ABCB1—lymph node—urinary bladder cancer	5.7e-05	0.00115	CbGeAlD
Diclofenac—Dizziness—Fluorouracil—urinary bladder cancer	3.67e-05	0.000333	CcSEcCtD
Diclofenac—Visual impairment—Epirubicin—urinary bladder cancer	3.66e-05	0.000333	CcSEcCtD
Diclofenac—Mediastinal disorder—Methotrexate—urinary bladder cancer	3.66e-05	0.000333	CcSEcCtD
Diclofenac—Agranulocytosis—Doxorubicin—urinary bladder cancer	3.66e-05	0.000332	CcSEcCtD
Diclofenac—Chills—Methotrexate—urinary bladder cancer	3.65e-05	0.000331	CcSEcCtD
Diclofenac—Diarrhoea—Cisplatin—urinary bladder cancer	3.6e-05	0.000327	CcSEcCtD
Diclofenac—Erythema multiforme—Epirubicin—urinary bladder cancer	3.59e-05	0.000326	CcSEcCtD
Diclofenac—Alopecia—Methotrexate—urinary bladder cancer	3.59e-05	0.000326	CcSEcCtD
Diclofenac—Vomiting—Gemcitabine—urinary bladder cancer	3.59e-05	0.000326	CcSEcCtD
Diclofenac—Bradycardia—Doxorubicin—urinary bladder cancer	3.58e-05	0.000325	CcSEcCtD
Diclofenac—Mental disorder—Methotrexate—urinary bladder cancer	3.56e-05	0.000323	CcSEcCtD
Diclofenac—Rash—Gemcitabine—urinary bladder cancer	3.56e-05	0.000323	CcSEcCtD
Diclofenac—Dermatitis—Gemcitabine—urinary bladder cancer	3.56e-05	0.000323	CcSEcCtD
Diclofenac—Eye disorder—Epirubicin—urinary bladder cancer	3.55e-05	0.000323	CcSEcCtD
Diclofenac—Hypersensitivity—Etoposide—urinary bladder cancer	3.55e-05	0.000322	CcSEcCtD
Diclofenac—Tinnitus—Epirubicin—urinary bladder cancer	3.55e-05	0.000322	CcSEcCtD
Diclofenac—Erythema—Methotrexate—urinary bladder cancer	3.54e-05	0.000321	CcSEcCtD
Diclofenac—Malnutrition—Methotrexate—urinary bladder cancer	3.54e-05	0.000321	CcSEcCtD
Diclofenac—Haemoglobin—Doxorubicin—urinary bladder cancer	3.54e-05	0.000321	CcSEcCtD
Diclofenac—Headache—Gemcitabine—urinary bladder cancer	3.54e-05	0.000321	CcSEcCtD
Diclofenac—Cardiac disorder—Epirubicin—urinary bladder cancer	3.53e-05	0.00032	CcSEcCtD
Diclofenac—Flushing—Epirubicin—urinary bladder cancer	3.53e-05	0.00032	CcSEcCtD
Diclofenac—Vomiting—Fluorouracil—urinary bladder cancer	3.53e-05	0.00032	CcSEcCtD
Diclofenac—Rhinitis—Doxorubicin—urinary bladder cancer	3.53e-05	0.00032	CcSEcCtD
Diclofenac—Haemorrhage—Doxorubicin—urinary bladder cancer	3.52e-05	0.000319	CcSEcCtD
Diclofenac—Hepatitis—Doxorubicin—urinary bladder cancer	3.52e-05	0.000319	CcSEcCtD
Diclofenac—Hypoaesthesia—Doxorubicin—urinary bladder cancer	3.5e-05	0.000318	CcSEcCtD
Diclofenac—Rash—Fluorouracil—urinary bladder cancer	3.5e-05	0.000318	CcSEcCtD
Diclofenac—Dermatitis—Fluorouracil—urinary bladder cancer	3.5e-05	0.000317	CcSEcCtD
Diclofenac—Pharyngitis—Doxorubicin—urinary bladder cancer	3.49e-05	0.000317	CcSEcCtD
Diclofenac—Headache—Fluorouracil—urinary bladder cancer	3.48e-05	0.000316	CcSEcCtD
Diclofenac—Urinary tract disorder—Doxorubicin—urinary bladder cancer	3.47e-05	0.000316	CcSEcCtD
Diclofenac—Oedema peripheral—Doxorubicin—urinary bladder cancer	3.47e-05	0.000315	CcSEcCtD
Diclofenac—Dysgeusia—Methotrexate—urinary bladder cancer	3.46e-05	0.000315	CcSEcCtD
Diclofenac—Asthenia—Etoposide—urinary bladder cancer	3.46e-05	0.000314	CcSEcCtD
Diclofenac—Angiopathy—Epirubicin—urinary bladder cancer	3.45e-05	0.000313	CcSEcCtD
Diclofenac—Urethral disorder—Doxorubicin—urinary bladder cancer	3.45e-05	0.000313	CcSEcCtD
Diclofenac—Immune system disorder—Epirubicin—urinary bladder cancer	3.43e-05	0.000312	CcSEcCtD
Diclofenac—Mediastinal disorder—Epirubicin—urinary bladder cancer	3.43e-05	0.000311	CcSEcCtD
Diclofenac—Back pain—Methotrexate—urinary bladder cancer	3.42e-05	0.000311	CcSEcCtD
Diclofenac—Chills—Epirubicin—urinary bladder cancer	3.41e-05	0.00031	CcSEcCtD
Diclofenac—Pruritus—Etoposide—urinary bladder cancer	3.41e-05	0.00031	CcSEcCtD
Diclofenac—Arrhythmia—Epirubicin—urinary bladder cancer	3.4e-05	0.000308	CcSEcCtD
Diclofenac—Visual impairment—Doxorubicin—urinary bladder cancer	3.39e-05	0.000308	CcSEcCtD
Diclofenac—Alopecia—Epirubicin—urinary bladder cancer	3.36e-05	0.000305	CcSEcCtD
Diclofenac—Nausea—Gemcitabine—urinary bladder cancer	3.35e-05	0.000304	CcSEcCtD
Diclofenac—Vomiting—Cisplatin—urinary bladder cancer	3.34e-05	0.000304	CcSEcCtD
Diclofenac—Vision blurred—Methotrexate—urinary bladder cancer	3.33e-05	0.000303	CcSEcCtD
Diclofenac—Mental disorder—Epirubicin—urinary bladder cancer	3.33e-05	0.000303	CcSEcCtD
Diclofenac—Erythema multiforme—Doxorubicin—urinary bladder cancer	3.33e-05	0.000302	CcSEcCtD
Diclofenac—Rash—Cisplatin—urinary bladder cancer	3.32e-05	0.000301	CcSEcCtD
Diclofenac—Dermatitis—Cisplatin—urinary bladder cancer	3.31e-05	0.000301	CcSEcCtD
Diclofenac—Erythema—Epirubicin—urinary bladder cancer	3.31e-05	0.000301	CcSEcCtD
Diclofenac—Malnutrition—Epirubicin—urinary bladder cancer	3.31e-05	0.000301	CcSEcCtD
Diclofenac—Diarrhoea—Etoposide—urinary bladder cancer	3.3e-05	0.000299	CcSEcCtD
Diclofenac—Nausea—Fluorouracil—urinary bladder cancer	3.3e-05	0.000299	CcSEcCtD
Diclofenac—Eye disorder—Doxorubicin—urinary bladder cancer	3.29e-05	0.000299	CcSEcCtD
Diclofenac—Ill-defined disorder—Methotrexate—urinary bladder cancer	3.28e-05	0.000298	CcSEcCtD
Diclofenac—Tinnitus—Doxorubicin—urinary bladder cancer	3.28e-05	0.000298	CcSEcCtD
Diclofenac—Anaemia—Methotrexate—urinary bladder cancer	3.27e-05	0.000297	CcSEcCtD
Diclofenac—Flushing—Doxorubicin—urinary bladder cancer	3.27e-05	0.000297	CcSEcCtD
Diclofenac—Cardiac disorder—Doxorubicin—urinary bladder cancer	3.27e-05	0.000297	CcSEcCtD
Diclofenac—Flatulence—Epirubicin—urinary bladder cancer	3.26e-05	0.000296	CcSEcCtD
Diclofenac—Tension—Epirubicin—urinary bladder cancer	3.25e-05	0.000295	CcSEcCtD
Diclofenac—Dysgeusia—Epirubicin—urinary bladder cancer	3.24e-05	0.000294	CcSEcCtD
Diclofenac—Nervousness—Epirubicin—urinary bladder cancer	3.21e-05	0.000292	CcSEcCtD
Diclofenac—Back pain—Epirubicin—urinary bladder cancer	3.2e-05	0.000291	CcSEcCtD
Diclofenac—Angiopathy—Doxorubicin—urinary bladder cancer	3.19e-05	0.00029	CcSEcCtD
Diclofenac—Malaise—Methotrexate—urinary bladder cancer	3.19e-05	0.00029	CcSEcCtD
Diclofenac—Dizziness—Etoposide—urinary bladder cancer	3.19e-05	0.000289	CcSEcCtD
Diclofenac—Muscle spasms—Epirubicin—urinary bladder cancer	3.18e-05	0.000289	CcSEcCtD
Diclofenac—Immune system disorder—Doxorubicin—urinary bladder cancer	3.18e-05	0.000289	CcSEcCtD
Diclofenac—Vertigo—Methotrexate—urinary bladder cancer	3.18e-05	0.000289	CcSEcCtD
Diclofenac—Mediastinal disorder—Doxorubicin—urinary bladder cancer	3.17e-05	0.000288	CcSEcCtD
Diclofenac—Leukopenia—Methotrexate—urinary bladder cancer	3.17e-05	0.000288	CcSEcCtD
Diclofenac—Chills—Doxorubicin—urinary bladder cancer	3.16e-05	0.000287	CcSEcCtD
Diclofenac—Arrhythmia—Doxorubicin—urinary bladder cancer	3.14e-05	0.000285	CcSEcCtD
Diclofenac—Nausea—Cisplatin—urinary bladder cancer	3.12e-05	0.000284	CcSEcCtD
Diclofenac—Vision blurred—Epirubicin—urinary bladder cancer	3.12e-05	0.000283	CcSEcCtD
Diclofenac—Alopecia—Doxorubicin—urinary bladder cancer	3.11e-05	0.000282	CcSEcCtD
Diclofenac—Cough—Methotrexate—urinary bladder cancer	3.09e-05	0.00028	CcSEcCtD
Diclofenac—Mental disorder—Doxorubicin—urinary bladder cancer	3.08e-05	0.00028	CcSEcCtD
Diclofenac—Ill-defined disorder—Epirubicin—urinary bladder cancer	3.07e-05	0.000279	CcSEcCtD
Diclofenac—Convulsion—Methotrexate—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Diclofenac—Vomiting—Etoposide—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Diclofenac—Erythema—Doxorubicin—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Diclofenac—Malnutrition—Doxorubicin—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Diclofenac—Anaemia—Epirubicin—urinary bladder cancer	3.06e-05	0.000278	CcSEcCtD
Diclofenac—Agitation—Epirubicin—urinary bladder cancer	3.04e-05	0.000276	CcSEcCtD
Diclofenac—Rash—Etoposide—urinary bladder cancer	3.04e-05	0.000276	CcSEcCtD
Diclofenac—Dermatitis—Etoposide—urinary bladder cancer	3.04e-05	0.000276	CcSEcCtD
Diclofenac—Headache—Etoposide—urinary bladder cancer	3.02e-05	0.000274	CcSEcCtD
Diclofenac—Flatulence—Doxorubicin—urinary bladder cancer	3.02e-05	0.000274	CcSEcCtD
Diclofenac—Myalgia—Methotrexate—urinary bladder cancer	3.01e-05	0.000273	CcSEcCtD
Diclofenac—Arthralgia—Methotrexate—urinary bladder cancer	3.01e-05	0.000273	CcSEcCtD
Diclofenac—Chest pain—Methotrexate—urinary bladder cancer	3.01e-05	0.000273	CcSEcCtD
Diclofenac—Tension—Doxorubicin—urinary bladder cancer	3.01e-05	0.000273	CcSEcCtD
Diclofenac—Dysgeusia—Doxorubicin—urinary bladder cancer	3e-05	0.000272	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	2.99e-05	0.000272	CcSEcCtD
Diclofenac—Malaise—Epirubicin—urinary bladder cancer	2.98e-05	0.000271	CcSEcCtD
Diclofenac—Discomfort—Methotrexate—urinary bladder cancer	2.97e-05	0.00027	CcSEcCtD
Diclofenac—Nervousness—Doxorubicin—urinary bladder cancer	2.97e-05	0.00027	CcSEcCtD
Diclofenac—Vertigo—Epirubicin—urinary bladder cancer	2.97e-05	0.00027	CcSEcCtD
Diclofenac—Syncope—Epirubicin—urinary bladder cancer	2.97e-05	0.00027	CcSEcCtD
Diclofenac—Leukopenia—Epirubicin—urinary bladder cancer	2.96e-05	0.000269	CcSEcCtD
Diclofenac—Back pain—Doxorubicin—urinary bladder cancer	2.96e-05	0.000269	CcSEcCtD
Diclofenac—Muscle spasms—Doxorubicin—urinary bladder cancer	2.94e-05	0.000267	CcSEcCtD
Diclofenac—Palpitations—Epirubicin—urinary bladder cancer	2.92e-05	0.000266	CcSEcCtD
Diclofenac—Confusional state—Methotrexate—urinary bladder cancer	2.91e-05	0.000264	CcSEcCtD
Diclofenac—Loss of consciousness—Epirubicin—urinary bladder cancer	2.91e-05	0.000264	CcSEcCtD
Diclofenac—Cough—Epirubicin—urinary bladder cancer	2.89e-05	0.000262	CcSEcCtD
Diclofenac—Anaphylactic shock—Methotrexate—urinary bladder cancer	2.89e-05	0.000262	CcSEcCtD
Diclofenac—Vision blurred—Doxorubicin—urinary bladder cancer	2.89e-05	0.000262	CcSEcCtD
Diclofenac—Convulsion—Epirubicin—urinary bladder cancer	2.87e-05	0.00026	CcSEcCtD
Diclofenac—Infection—Methotrexate—urinary bladder cancer	2.87e-05	0.00026	CcSEcCtD
Diclofenac—Nausea—Etoposide—urinary bladder cancer	2.86e-05	0.00026	CcSEcCtD
Diclofenac—Hypertension—Epirubicin—urinary bladder cancer	2.86e-05	0.00026	CcSEcCtD
Diclofenac—Ill-defined disorder—Doxorubicin—urinary bladder cancer	2.84e-05	0.000258	CcSEcCtD
Diclofenac—Nervous system disorder—Methotrexate—urinary bladder cancer	2.83e-05	0.000257	CcSEcCtD
Diclofenac—Anaemia—Doxorubicin—urinary bladder cancer	2.83e-05	0.000257	CcSEcCtD
Diclofenac—Thrombocytopenia—Methotrexate—urinary bladder cancer	2.83e-05	0.000257	CcSEcCtD
Diclofenac—Chest pain—Epirubicin—urinary bladder cancer	2.82e-05	0.000256	CcSEcCtD
Diclofenac—Arthralgia—Epirubicin—urinary bladder cancer	2.82e-05	0.000256	CcSEcCtD
Diclofenac—Myalgia—Epirubicin—urinary bladder cancer	2.82e-05	0.000256	CcSEcCtD
Diclofenac—Agitation—Doxorubicin—urinary bladder cancer	2.81e-05	0.000256	CcSEcCtD
Diclofenac—Anxiety—Epirubicin—urinary bladder cancer	2.81e-05	0.000255	CcSEcCtD
Diclofenac—Skin disorder—Methotrexate—urinary bladder cancer	2.8e-05	0.000255	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	2.8e-05	0.000254	CcSEcCtD
Diclofenac—Hyperhidrosis—Methotrexate—urinary bladder cancer	2.79e-05	0.000253	CcSEcCtD
Diclofenac—Discomfort—Epirubicin—urinary bladder cancer	2.78e-05	0.000253	CcSEcCtD
Diclofenac—Malaise—Doxorubicin—urinary bladder cancer	2.76e-05	0.000251	CcSEcCtD
Diclofenac—Dry mouth—Epirubicin—urinary bladder cancer	2.76e-05	0.00025	CcSEcCtD
Diclofenac—Vertigo—Doxorubicin—urinary bladder cancer	2.75e-05	0.00025	CcSEcCtD
Diclofenac—Anorexia—Methotrexate—urinary bladder cancer	2.75e-05	0.00025	CcSEcCtD
Diclofenac—Syncope—Doxorubicin—urinary bladder cancer	2.75e-05	0.000249	CcSEcCtD
Diclofenac—Leukopenia—Doxorubicin—urinary bladder cancer	2.74e-05	0.000249	CcSEcCtD
Diclofenac—Confusional state—Epirubicin—urinary bladder cancer	2.72e-05	0.000247	CcSEcCtD
Diclofenac—Palpitations—Doxorubicin—urinary bladder cancer	2.71e-05	0.000246	CcSEcCtD
Diclofenac—Oedema—Epirubicin—urinary bladder cancer	2.7e-05	0.000245	CcSEcCtD
Diclofenac—Anaphylactic shock—Epirubicin—urinary bladder cancer	2.7e-05	0.000245	CcSEcCtD
Diclofenac—Hypotension—Methotrexate—urinary bladder cancer	2.7e-05	0.000245	CcSEcCtD
Diclofenac—Loss of consciousness—Doxorubicin—urinary bladder cancer	2.69e-05	0.000244	CcSEcCtD
Diclofenac—Infection—Epirubicin—urinary bladder cancer	2.68e-05	0.000244	CcSEcCtD
Diclofenac—Cough—Doxorubicin—urinary bladder cancer	2.67e-05	0.000243	CcSEcCtD
Diclofenac—Shock—Epirubicin—urinary bladder cancer	2.66e-05	0.000241	CcSEcCtD
Diclofenac—Convulsion—Doxorubicin—urinary bladder cancer	2.65e-05	0.000241	CcSEcCtD
Diclofenac—Nervous system disorder—Epirubicin—urinary bladder cancer	2.65e-05	0.000241	CcSEcCtD
Diclofenac—Thrombocytopenia—Epirubicin—urinary bladder cancer	2.64e-05	0.00024	CcSEcCtD
Diclofenac—Hypertension—Doxorubicin—urinary bladder cancer	2.64e-05	0.00024	CcSEcCtD
Diclofenac—Tachycardia—Epirubicin—urinary bladder cancer	2.64e-05	0.000239	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	2.63e-05	0.000239	CcSEcCtD
Diclofenac—Skin disorder—Epirubicin—urinary bladder cancer	2.62e-05	0.000238	CcSEcCtD
Diclofenac—Hyperhidrosis—Epirubicin—urinary bladder cancer	2.61e-05	0.000237	CcSEcCtD
Diclofenac—Insomnia—Methotrexate—urinary bladder cancer	2.61e-05	0.000237	CcSEcCtD
Diclofenac—Chest pain—Doxorubicin—urinary bladder cancer	2.61e-05	0.000237	CcSEcCtD
Diclofenac—Arthralgia—Doxorubicin—urinary bladder cancer	2.61e-05	0.000237	CcSEcCtD
Diclofenac—Myalgia—Doxorubicin—urinary bladder cancer	2.61e-05	0.000237	CcSEcCtD
Diclofenac—Anxiety—Doxorubicin—urinary bladder cancer	2.6e-05	0.000236	CcSEcCtD
Diclofenac—Paraesthesia—Methotrexate—urinary bladder cancer	2.59e-05	0.000235	CcSEcCtD
Diclofenac—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	2.59e-05	0.000235	CcSEcCtD
Diclofenac—Discomfort—Doxorubicin—urinary bladder cancer	2.58e-05	0.000234	CcSEcCtD
Diclofenac—Anorexia—Epirubicin—urinary bladder cancer	2.57e-05	0.000234	CcSEcCtD
Diclofenac—Dyspnoea—Methotrexate—urinary bladder cancer	2.57e-05	0.000234	CcSEcCtD
Diclofenac—Somnolence—Methotrexate—urinary bladder cancer	2.57e-05	0.000233	CcSEcCtD
Diclofenac—Dry mouth—Doxorubicin—urinary bladder cancer	2.55e-05	0.000232	CcSEcCtD
Diclofenac—Dyspepsia—Methotrexate—urinary bladder cancer	2.54e-05	0.000231	CcSEcCtD
Diclofenac—Hypotension—Epirubicin—urinary bladder cancer	2.52e-05	0.000229	CcSEcCtD
Diclofenac—Confusional state—Doxorubicin—urinary bladder cancer	2.52e-05	0.000229	CcSEcCtD
Diclofenac—Decreased appetite—Methotrexate—urinary bladder cancer	2.51e-05	0.000228	CcSEcCtD
Diclofenac—Oedema—Doxorubicin—urinary bladder cancer	2.5e-05	0.000227	CcSEcCtD
Diclofenac—Anaphylactic shock—Doxorubicin—urinary bladder cancer	2.5e-05	0.000227	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	2.49e-05	0.000226	CcSEcCtD
Diclofenac—Fatigue—Methotrexate—urinary bladder cancer	2.49e-05	0.000226	CcSEcCtD
Diclofenac—Infection—Doxorubicin—urinary bladder cancer	2.48e-05	0.000225	CcSEcCtD
Diclofenac—Pain—Methotrexate—urinary bladder cancer	2.47e-05	0.000224	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	2.46e-05	0.000223	CcSEcCtD
Diclofenac—Shock—Doxorubicin—urinary bladder cancer	2.46e-05	0.000223	CcSEcCtD
Diclofenac—Nervous system disorder—Doxorubicin—urinary bladder cancer	2.45e-05	0.000223	CcSEcCtD
Diclofenac—Thrombocytopenia—Doxorubicin—urinary bladder cancer	2.45e-05	0.000222	CcSEcCtD
Diclofenac—Insomnia—Epirubicin—urinary bladder cancer	2.44e-05	0.000222	CcSEcCtD
Diclofenac—Tachycardia—Doxorubicin—urinary bladder cancer	2.44e-05	0.000222	CcSEcCtD
Diclofenac—Skin disorder—Doxorubicin—urinary bladder cancer	2.43e-05	0.00022	CcSEcCtD
Diclofenac—Paraesthesia—Epirubicin—urinary bladder cancer	2.43e-05	0.00022	CcSEcCtD
Diclofenac—Hyperhidrosis—Doxorubicin—urinary bladder cancer	2.42e-05	0.000219	CcSEcCtD
Diclofenac—Dyspnoea—Epirubicin—urinary bladder cancer	2.41e-05	0.000219	CcSEcCtD
Diclofenac—Somnolence—Epirubicin—urinary bladder cancer	2.4e-05	0.000218	CcSEcCtD
Diclofenac—Anorexia—Doxorubicin—urinary bladder cancer	2.38e-05	0.000216	CcSEcCtD
Diclofenac—Feeling abnormal—Methotrexate—urinary bladder cancer	2.38e-05	0.000216	CcSEcCtD
Diclofenac—Dyspepsia—Epirubicin—urinary bladder cancer	2.38e-05	0.000216	CcSEcCtD
Diclofenac—Gastrointestinal pain—Methotrexate—urinary bladder cancer	2.36e-05	0.000214	CcSEcCtD
Diclofenac—Decreased appetite—Epirubicin—urinary bladder cancer	2.35e-05	0.000213	CcSEcCtD
Diclofenac—Hypotension—Doxorubicin—urinary bladder cancer	2.34e-05	0.000212	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	2.33e-05	0.000212	CcSEcCtD
Diclofenac—Fatigue—Epirubicin—urinary bladder cancer	2.33e-05	0.000211	CcSEcCtD
Diclofenac—Pain—Epirubicin—urinary bladder cancer	2.31e-05	0.00021	CcSEcCtD
Diclofenac—Constipation—Epirubicin—urinary bladder cancer	2.31e-05	0.00021	CcSEcCtD
Diclofenac—Urticaria—Methotrexate—urinary bladder cancer	2.29e-05	0.000208	CcSEcCtD
Diclofenac—Abdominal pain—Methotrexate—urinary bladder cancer	2.28e-05	0.000207	CcSEcCtD
Diclofenac—Body temperature increased—Methotrexate—urinary bladder cancer	2.28e-05	0.000207	CcSEcCtD
Diclofenac—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	2.28e-05	0.000207	CcSEcCtD
Diclofenac—Insomnia—Doxorubicin—urinary bladder cancer	2.26e-05	0.000205	CcSEcCtD
Diclofenac—Paraesthesia—Doxorubicin—urinary bladder cancer	2.24e-05	0.000204	CcSEcCtD
Diclofenac—Dyspnoea—Doxorubicin—urinary bladder cancer	2.23e-05	0.000202	CcSEcCtD
Diclofenac—Feeling abnormal—Epirubicin—urinary bladder cancer	2.23e-05	0.000202	CcSEcCtD
Diclofenac—Somnolence—Doxorubicin—urinary bladder cancer	2.22e-05	0.000202	CcSEcCtD
Diclofenac—Gastrointestinal pain—Epirubicin—urinary bladder cancer	2.21e-05	0.000201	CcSEcCtD
Diclofenac—Dyspepsia—Doxorubicin—urinary bladder cancer	2.2e-05	0.0002	CcSEcCtD
Diclofenac—Decreased appetite—Doxorubicin—urinary bladder cancer	2.17e-05	0.000197	CcSEcCtD
Diclofenac—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	2.16e-05	0.000196	CcSEcCtD
Diclofenac—Fatigue—Doxorubicin—urinary bladder cancer	2.15e-05	0.000196	CcSEcCtD
Diclofenac—Urticaria—Epirubicin—urinary bladder cancer	2.15e-05	0.000195	CcSEcCtD
Diclofenac—Pain—Doxorubicin—urinary bladder cancer	2.14e-05	0.000194	CcSEcCtD
Diclofenac—Constipation—Doxorubicin—urinary bladder cancer	2.14e-05	0.000194	CcSEcCtD
Diclofenac—Abdominal pain—Epirubicin—urinary bladder cancer	2.14e-05	0.000194	CcSEcCtD
Diclofenac—Body temperature increased—Epirubicin—urinary bladder cancer	2.14e-05	0.000194	CcSEcCtD
Diclofenac—Hypersensitivity—Methotrexate—urinary bladder cancer	2.13e-05	0.000193	CcSEcCtD
Diclofenac—Asthenia—Methotrexate—urinary bladder cancer	2.07e-05	0.000188	CcSEcCtD
Diclofenac—Feeling abnormal—Doxorubicin—urinary bladder cancer	2.06e-05	0.000187	CcSEcCtD
Diclofenac—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	2.04e-05	0.000186	CcSEcCtD
Diclofenac—Pruritus—Methotrexate—urinary bladder cancer	2.04e-05	0.000185	CcSEcCtD
Diclofenac—Hypersensitivity—Epirubicin—urinary bladder cancer	1.99e-05	0.000181	CcSEcCtD
Diclofenac—Urticaria—Doxorubicin—urinary bladder cancer	1.99e-05	0.00018	CcSEcCtD
Diclofenac—Body temperature increased—Doxorubicin—urinary bladder cancer	1.98e-05	0.000179	CcSEcCtD
Diclofenac—Abdominal pain—Doxorubicin—urinary bladder cancer	1.98e-05	0.000179	CcSEcCtD
Diclofenac—Diarrhoea—Methotrexate—urinary bladder cancer	1.97e-05	0.000179	CcSEcCtD
Diclofenac—Asthenia—Epirubicin—urinary bladder cancer	1.94e-05	0.000176	CcSEcCtD
Diclofenac—Pruritus—Epirubicin—urinary bladder cancer	1.91e-05	0.000174	CcSEcCtD
Diclofenac—Dizziness—Methotrexate—urinary bladder cancer	1.91e-05	0.000173	CcSEcCtD
Diclofenac—Diarrhoea—Epirubicin—urinary bladder cancer	1.85e-05	0.000168	CcSEcCtD
Diclofenac—Hypersensitivity—Doxorubicin—urinary bladder cancer	1.84e-05	0.000167	CcSEcCtD
Diclofenac—Vomiting—Methotrexate—urinary bladder cancer	1.84e-05	0.000167	CcSEcCtD
Diclofenac—Rash—Methotrexate—urinary bladder cancer	1.82e-05	0.000165	CcSEcCtD
Diclofenac—Dermatitis—Methotrexate—urinary bladder cancer	1.82e-05	0.000165	CcSEcCtD
Diclofenac—Headache—Methotrexate—urinary bladder cancer	1.81e-05	0.000164	CcSEcCtD
Diclofenac—Asthenia—Doxorubicin—urinary bladder cancer	1.79e-05	0.000163	CcSEcCtD
Diclofenac—Dizziness—Epirubicin—urinary bladder cancer	1.79e-05	0.000162	CcSEcCtD
Diclofenac—Pruritus—Doxorubicin—urinary bladder cancer	1.77e-05	0.000161	CcSEcCtD
Diclofenac—Vomiting—Epirubicin—urinary bladder cancer	1.72e-05	0.000156	CcSEcCtD
Diclofenac—Nausea—Methotrexate—urinary bladder cancer	1.71e-05	0.000156	CcSEcCtD
Diclofenac—Diarrhoea—Doxorubicin—urinary bladder cancer	1.71e-05	0.000155	CcSEcCtD
Diclofenac—Rash—Epirubicin—urinary bladder cancer	1.7e-05	0.000155	CcSEcCtD
Diclofenac—Dermatitis—Epirubicin—urinary bladder cancer	1.7e-05	0.000155	CcSEcCtD
Diclofenac—Headache—Epirubicin—urinary bladder cancer	1.69e-05	0.000154	CcSEcCtD
Diclofenac—Dizziness—Doxorubicin—urinary bladder cancer	1.65e-05	0.00015	CcSEcCtD
Diclofenac—Nausea—Epirubicin—urinary bladder cancer	1.6e-05	0.000146	CcSEcCtD
Diclofenac—Vomiting—Doxorubicin—urinary bladder cancer	1.59e-05	0.000144	CcSEcCtD
Diclofenac—Rash—Doxorubicin—urinary bladder cancer	1.58e-05	0.000143	CcSEcCtD
Diclofenac—Dermatitis—Doxorubicin—urinary bladder cancer	1.57e-05	0.000143	CcSEcCtD
Diclofenac—Headache—Doxorubicin—urinary bladder cancer	1.57e-05	0.000142	CcSEcCtD
Diclofenac—Nausea—Doxorubicin—urinary bladder cancer	1.48e-05	0.000135	CcSEcCtD
Diclofenac—TTR—Signaling Pathways—EGFR—urinary bladder cancer	3.95e-06	5.3e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.9e-06	5.23e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.9e-06	5.23e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—ERCC2—urinary bladder cancer	3.9e-06	5.23e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—MTHFR—urinary bladder cancer	3.87e-06	5.19e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.86e-06	5.18e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—RHOA—urinary bladder cancer	3.85e-06	5.16e-05	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—PPARG—urinary bladder cancer	3.85e-06	5.16e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.83e-06	5.14e-05	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—PTGS2—urinary bladder cancer	3.83e-06	5.13e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—ERBB2—urinary bladder cancer	3.82e-06	5.13e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—GSTP1—urinary bladder cancer	3.78e-06	5.07e-05	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—KRAS—urinary bladder cancer	3.73e-06	5.01e-05	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—PTGS2—urinary bladder cancer	3.72e-06	4.99e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.72e-06	4.99e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.72e-06	4.99e-05	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—PPARG—urinary bladder cancer	3.71e-06	4.97e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.7e-06	4.96e-05	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	3.69e-06	4.96e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.69e-06	4.95e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—NQO1—urinary bladder cancer	3.67e-06	4.92e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—MTHFR—urinary bladder cancer	3.66e-06	4.92e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.66e-06	4.9e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—TERT—urinary bladder cancer	3.65e-06	4.9e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—GSTP1—urinary bladder cancer	3.63e-06	4.87e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—IL2—urinary bladder cancer	3.62e-06	4.86e-05	CbGpPWpGaD
Diclofenac—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.62e-06	4.85e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.61e-06	4.84e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling by GPCR—HRAS—urinary bladder cancer	3.6e-06	4.83e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.58e-06	4.8e-05	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—CREBBP—urinary bladder cancer	3.56e-06	4.78e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—ERBB2—urinary bladder cancer	3.56e-06	4.78e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—GSTP1—urinary bladder cancer	3.56e-06	4.77e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.56e-06	4.77e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.56e-06	4.77e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—TYMS—urinary bladder cancer	3.51e-06	4.71e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—PTGS2—urinary bladder cancer	3.48e-06	4.67e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—NCOR1—urinary bladder cancer	3.47e-06	4.66e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—GSTM1—urinary bladder cancer	3.47e-06	4.66e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—IL2—urinary bladder cancer	3.46e-06	4.65e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—RRM2—urinary bladder cancer	3.43e-06	4.61e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.4e-06	4.56e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—TYMP—urinary bladder cancer	3.4e-06	4.56e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CCND1—urinary bladder cancer	3.38e-06	4.53e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—TYMS—urinary bladder cancer	3.38e-06	4.53e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	3.35e-06	4.5e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—FGFR3—urinary bladder cancer	3.35e-06	4.5e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—NCOR1—urinary bladder cancer	3.34e-06	4.48e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—GSTM1—urinary bladder cancer	3.34e-06	4.48e-05	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—PTEN—urinary bladder cancer	3.34e-06	4.48e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—GPX1—urinary bladder cancer	3.33e-06	4.46e-05	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—TP53—urinary bladder cancer	3.32e-06	4.45e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—TYMS—urinary bladder cancer	3.31e-06	4.44e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—NQO1—urinary bladder cancer	3.29e-06	4.41e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—MMP9—urinary bladder cancer	3.28e-06	4.4e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—GSTM1—urinary bladder cancer	3.27e-06	4.39e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—NCOR1—urinary bladder cancer	3.27e-06	4.39e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—CDKN1A—urinary bladder cancer	3.27e-06	4.38e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—ERCC2—urinary bladder cancer	3.27e-06	4.38e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—PTEN—urinary bladder cancer	3.26e-06	4.37e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—EP300—urinary bladder cancer	3.25e-06	4.36e-05	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—PTEN—urinary bladder cancer	3.25e-06	4.36e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.24e-06	4.35e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—NQO1—urinary bladder cancer	3.21e-06	4.31e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—GPX1—urinary bladder cancer	3.2e-06	4.29e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.19e-06	4.28e-05	CbGpPWpGaD
Diclofenac—CYP2C18—Metabolism—EP300—urinary bladder cancer	3.18e-06	4.27e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—ENO2—urinary bladder cancer	3.18e-06	4.27e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	3.18e-06	4.27e-05	CbGpPWpGaD
Diclofenac—TTR—Signaling Pathways—HRAS—urinary bladder cancer	3.17e-06	4.25e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.16e-06	4.24e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—SRC—urinary bladder cancer	3.16e-06	4.24e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—ERCC2—urinary bladder cancer	3.14e-06	4.21e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—PPARG—urinary bladder cancer	3.14e-06	4.21e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—GPX1—urinary bladder cancer	3.13e-06	4.2e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.12e-06	4.18e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—TYMS—urinary bladder cancer	3.12e-06	4.18e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—EP300—urinary bladder cancer	3.11e-06	4.17e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.1e-06	4.16e-05	CbGpPWpGaD
Diclofenac—UGT2B7—Metabolism—EP300—urinary bladder cancer	3.1e-06	4.15e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	3.09e-06	4.14e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	3.08e-06	4.13e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	3.08e-06	4.13e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	3.07e-06	4.13e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—ERCC2—urinary bladder cancer	3.07e-06	4.12e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—NAT2—urinary bladder cancer	3.07e-06	4.12e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—MTHFR—urinary bladder cancer	3.07e-06	4.12e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—GSTP1—urinary bladder cancer	3.06e-06	4.1e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—CDKN1A—urinary bladder cancer	3.04e-06	4.08e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.04e-06	4.08e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—PTEN—urinary bladder cancer	3.04e-06	4.08e-05	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	3.03e-06	4.06e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—SRC—urinary bladder cancer	3.02e-06	4.05e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—CREBBP—urinary bladder cancer	3.01e-06	4.04e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—NQO1—urinary bladder cancer	3e-06	4.03e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.97e-06	3.99e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.96e-06	3.97e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—GPX1—urinary bladder cancer	2.95e-06	3.96e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—MTHFR—urinary bladder cancer	2.95e-06	3.96e-05	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—PTGS2—urinary bladder cancer	2.92e-06	3.91e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.91e-06	3.91e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	2.9e-06	3.89e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—EP300—urinary bladder cancer	2.9e-06	3.89e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—MTHFR—urinary bladder cancer	2.89e-06	3.88e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.86e-06	3.83e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CREBBP—urinary bladder cancer	2.85e-06	3.83e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—TYMS—urinary bladder cancer	2.84e-06	3.81e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.83e-06	3.79e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.83e-06	3.79e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—SRC—urinary bladder cancer	2.82e-06	3.78e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—GSTM1—urinary bladder cancer	2.81e-06	3.77e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—NCOR1—urinary bladder cancer	2.81e-06	3.77e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.78e-06	3.74e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.74e-06	3.68e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	2.72e-06	3.65e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—MYC—urinary bladder cancer	2.71e-06	3.63e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.71e-06	3.63e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—GPX1—urinary bladder cancer	2.69e-06	3.61e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.68e-06	3.59e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.66e-06	3.56e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.66e-06	3.56e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.65e-06	3.56e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—EGFR—urinary bladder cancer	2.65e-06	3.55e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—ERCC2—urinary bladder cancer	2.64e-06	3.54e-05	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—PTEN—urinary bladder cancer	2.64e-06	3.54e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—KRAS—urinary bladder cancer	2.62e-06	3.51e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—RHOA—urinary bladder cancer	2.58e-06	3.46e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—NQO1—urinary bladder cancer	2.56e-06	3.44e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.55e-06	3.42e-05	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—PTEN—urinary bladder cancer	2.54e-06	3.41e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.54e-06	3.41e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—MYC—urinary bladder cancer	2.52e-06	3.39e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2.52e-06	3.38e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2.52e-06	3.38e-05	CbGpPWpGaD
Diclofenac—UGT1A1—Metabolism—EP300—urinary bladder cancer	2.52e-06	3.38e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—KRAS—urinary bladder cancer	2.5e-06	3.36e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.5e-06	3.36e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.5e-06	3.35e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—TYMS—urinary bladder cancer	2.49e-06	3.34e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—PPARG—urinary bladder cancer	2.49e-06	3.34e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.49e-06	3.34e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—MTHFR—urinary bladder cancer	2.48e-06	3.33e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—EGFR—urinary bladder cancer	2.47e-06	3.31e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—PTGS2—urinary bladder cancer	2.47e-06	3.31e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—NCOR1—urinary bladder cancer	2.46e-06	3.3e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—GSTM1—urinary bladder cancer	2.46e-06	3.3e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	2.46e-06	3.29e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—ENO2—urinary bladder cancer	2.46e-06	3.29e-05	CbGpPWpGaD
Diclofenac—ABCC1—Metabolism—EP300—urinary bladder cancer	2.43e-06	3.25e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.42e-06	3.25e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—GPX1—urinary bladder cancer	2.42e-06	3.24e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—PPARG—urinary bladder cancer	2.39e-06	3.21e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—CREBBP—urinary bladder cancer	2.39e-06	3.21e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—ERBB2—urinary bladder cancer	2.39e-06	3.21e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	2.38e-06	3.19e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	2.37e-06	3.18e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—GPX1—urinary bladder cancer	2.36e-06	3.16e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—PPARG—urinary bladder cancer	2.34e-06	3.14e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—KRAS—urinary bladder cancer	2.33e-06	3.13e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.33e-06	3.12e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—TP53—urinary bladder cancer	2.33e-06	3.12e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—ERCC2—urinary bladder cancer	2.31e-06	3.11e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.3e-06	3.09e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.3e-06	3.09e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—CREBBP—urinary bladder cancer	2.3e-06	3.08e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—CREBBP—urinary bladder cancer	2.25e-06	3.02e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	2.23e-06	2.99e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—TP53—urinary bladder cancer	2.22e-06	2.98e-05	CbGpPWpGaD
Diclofenac—ALB—Hemostasis—HRAS—urinary bladder cancer	2.22e-06	2.98e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—PPARG—urinary bladder cancer	2.21e-06	2.96e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.2e-06	2.95e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—MTHFR—urinary bladder cancer	2.18e-06	2.92e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.17e-06	2.91e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.16e-06	2.9e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—PTEN—urinary bladder cancer	2.15e-06	2.89e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.14e-06	2.87e-05	CbGpPWpGaD
Diclofenac—CXCL8—Signaling Pathways—HRAS—urinary bladder cancer	2.13e-06	2.85e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	2.12e-06	2.85e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.07e-06	2.78e-05	CbGpPWpGaD
Diclofenac—PTGS1—Metabolism—EP300—urinary bladder cancer	2.05e-06	2.75e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—CDKN1A—urinary bladder cancer	2.04e-06	2.74e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—PTEN—urinary bladder cancer	2.04e-06	2.74e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	2.03e-06	2.73e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—PPARG—urinary bladder cancer	2.03e-06	2.72e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—PPARG—urinary bladder cancer	2.01e-06	2.7e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—TYMS—urinary bladder cancer	1.99e-06	2.67e-05	CbGpPWpGaD
Diclofenac—ABCC1—Disease—HRAS—urinary bladder cancer	1.98e-06	2.66e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.98e-06	2.65e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	1.97e-06	2.64e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	1.97e-06	2.64e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.95e-06	2.61e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—EP300—urinary bladder cancer	1.94e-06	2.61e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—CREBBP—urinary bladder cancer	1.93e-06	2.59e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—SRC—urinary bladder cancer	1.89e-06	2.54e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.88e-06	2.52e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—PTGS2—urinary bladder cancer	1.88e-06	2.52e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.85e-06	2.48e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—PTGS2—urinary bladder cancer	1.84e-06	2.47e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.81e-06	2.42e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.76e-06	2.37e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	1.74e-06	2.33e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.74e-06	2.33e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.74e-06	2.33e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—PTEN—urinary bladder cancer	1.71e-06	2.29e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.69e-06	2.27e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—MYC—urinary bladder cancer	1.69e-06	2.27e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—EGFR—urinary bladder cancer	1.66e-06	2.22e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.65e-06	2.21e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.65e-06	2.21e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—PTEN—urinary bladder cancer	1.64e-06	2.2e-05	CbGpPWpGaD
Diclofenac—PTGS2—Metabolism—EP300—urinary bladder cancer	1.63e-06	2.18e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—PTEN—urinary bladder cancer	1.61e-06	2.16e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.59e-06	2.14e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—PTGS2—urinary bladder cancer	1.58e-06	2.12e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.58e-06	2.12e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—KRAS—urinary bladder cancer	1.57e-06	2.1e-05	CbGpPWpGaD
Diclofenac—CYP2B6—Metabolism—EP300—urinary bladder cancer	1.56e-06	2.1e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.53e-06	2.06e-05	CbGpPWpGaD
Diclofenac—CYP2E1—Metabolism—EP300—urinary bladder cancer	1.53e-06	2.06e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.52e-06	2.03e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.52e-06	2.03e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—PTEN—urinary bladder cancer	1.52e-06	2.03e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.45e-06	1.95e-05	CbGpPWpGaD
Diclofenac—CYP1A1—Metabolism—EP300—urinary bladder cancer	1.45e-06	1.94e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.43e-06	1.91e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.42e-06	1.91e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.41e-06	1.89e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.39e-06	1.86e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.39e-06	1.86e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—PTEN—urinary bladder cancer	1.38e-06	1.85e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.35e-06	1.82e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.34e-06	1.8e-05	CbGpPWpGaD
Diclofenac—PTGS2—Disease—HRAS—urinary bladder cancer	1.33e-06	1.79e-05	CbGpPWpGaD
Diclofenac—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.32e-06	1.78e-05	CbGpPWpGaD
Diclofenac—ALB—Metabolism—EP300—urinary bladder cancer	1.32e-06	1.77e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.3e-06	1.74e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—PTEN—urinary bladder cancer	1.24e-06	1.66e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—PTEN—urinary bladder cancer	1.21e-06	1.62e-05	CbGpPWpGaD
Diclofenac—CYP2C19—Metabolism—EP300—urinary bladder cancer	1.18e-06	1.59e-05	CbGpPWpGaD
Diclofenac—ABCB1—Metabolism—EP300—urinary bladder cancer	1.15e-06	1.55e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.13e-06	1.52e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.11e-06	1.49e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.09e-06	1.46e-05	CbGpPWpGaD
Diclofenac—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.08e-06	1.45e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.04e-06	1.4e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—PTEN—urinary bladder cancer	9.66e-07	1.3e-05	CbGpPWpGaD
Diclofenac—CYP1A2—Metabolism—EP300—urinary bladder cancer	9.21e-07	1.24e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.55e-07	1.15e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.46e-07	1e-05	CbGpPWpGaD
Diclofenac—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.11e-07	9.54e-06	CbGpPWpGaD
